Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000518921 | SCV000618426 | pathogenic | not provided | 2023-02-24 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 31785789, 29165669, 19344873, 33798445, 34445196) |
Ambry Genetics | RCV000624265 | SCV000742698 | uncertain significance | Inborn genetic diseases | 2017-07-17 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV001095766 | SCV001251609 | likely pathogenic | CACNA1A-related disorders | 2020-01-24 | criteria provided, single submitter | clinical testing | The CACNA1A c.4900G>A (p.Asp1634Asn) variant is a missense variant. It is reported as a de novo variant, though without confirmed parentage, in one individual in the DECIPHER database (Firth et al. 2009, patient 259278). The reported phenotype of this individual is consistent with CACNA1A-related disorders and includes global developmental delay, intellectual disability, sleep disturbance, unsteady gait, falls, behavioral abnormalities, brachycephaly, strabismus, and bilateral single transverse palmar creases. The p.Asp1634Asn variant has also been identified by clinical laboratories in individuals with neurodevelopmental phenotypes consistent with CACNA1A-related disorders and submitted to the ClinVar database (Landrum et al. 2018); however these cases are not reported in the published literature and clinical details are limited. This variant is not found in the Genome Aggregation Database in a region of good sequencing coverage, so the variant is presumed to be rare. The p.Asp1634Asn variant occurs at a conserved residue in the S3 transmembrane segment of domain IV of the voltage-dependent P/Q-type calcium channel subunit alpha-1A protein, though the function of this region is unknown. In silico predictions suggest a damaging consequence, however this has not been evaluated experimentally. Based on the collective evidence and the application of ACMG criteria, the p.Asp1634Asn variant is classified as likely pathogenic for CACNA1A-related disorders. |
Molecular Medicine for Neurodegenerative and Neuromuscular Diseases Unit, |
RCV001644622 | SCV001519108 | pathogenic | Episodic ataxia type 2 | 2021-01-04 | criteria provided, single submitter | research | |
Wendy Chung Laboratory, |
RCV002227176 | SCV002506524 | likely pathogenic | Episodic ataxia type 2; Spinocerebellar ataxia type 6; Migraine, familial hemiplegic, 1; Developmental and epileptic encephalopathy, 52 | 2022-03-20 | criteria provided, single submitter | clinical testing |